Abdominal neoplastic manifestations of neurofibromatosis type 1

Abstract Neurofibromatosis type 1 (NF1) is an autosomal dominant hereditary tumor syndrome, with a wide clinicopathologic spectrum. It is defined by characteristic central nervous system, cutaneous and osseous manifestations, and by mutations in the NF1 gene, which is involved in proliferation via p21, RAS, and MAP kinase pathways. Up to 25% of NF1 patients develop intra-abdominal neoplastic manifestations including neurogenic (commonly plexiform neurofibromas and malignant peripheral nerve sheath tumors), interstitial cells of Cajal (hyperplasia, gastrointestinal stromal tumors), neuroendocrine, and embryonal tumors (rhabdomyosarcoma). Nonspecific symptoms, multifocal disease, or coexistence of 2 or more tumor types make patients challenging to diagnose and manage. Screening for intra-abdominal tumors in NF1 patients remains controversial, and currently no guidelines are established. Management decisions are complex and often informed by single-center experiences or case studies in the literature, though the field is rapidly evolving. Thus, NF1 patients should be followed in specialist centers familiar with their wide spectrum of pathology and with multidisciplinary care including specialized pathology and radiology. This review will (1) provide a contemporaneous synthesis of the literature and our multi-institutional clinical experiences with intra-abdominal neoplasms in NF1 patients, (2) present a classification framework for this heterogeneous group of disorders, and (3) outline approaches to screening, surveillance, diagnosis, and management.

[1]  L. Fayad,et al.  Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis , 2019, Skeletal Radiology.

[2]  B. Dickson,et al.  Early and Late Complications of Percutaneous Core Needle Biopsy of Retroperitoneal Tumors at Two Tertiary Sarcoma Centers , 2019, Annals of Surgical Oncology.

[3]  F. Dehdashti,et al.  How Effective Are Noninvasive Tests for Diagnosing Malignant Peripheral Nerve Sheath Tumors in Patients with Neurofibromatosis Type 1? Diagnosing MPNST in NF1 Patients , 2019, Sarcoma.

[4]  K. McHugh,et al.  Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS‐2005 prospective study , 2019, Pediatric blood & cancer.

[5]  B. Bender,et al.  Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  T. Derlin,et al.  Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging , 2018, Neuro-oncology.

[7]  T. Else,et al.  Pheochromocytoma and Paraganglioma in Neurofibromatosis type 1: frequent surgeries and cardiovascular crises indicate the need for screening , 2018, Clinical Diabetes and Endocrinology.

[8]  S. Steinberg,et al.  NFM-07. SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN) , 2018, Neuro-Oncology.

[9]  M. Dhir,et al.  Nonoperative Management May Be a Viable Approach to Plexiform Neurofibroma of the Porta Hepatis in Patients with Neurofibromatosis-1 , 2018, HPB surgery : a world journal of hepatic, pancreatic and biliary surgery.

[10]  Y. Oda,et al.  Immunohistochemical evaluation of H3K27 trimethylation in malignant peripheral nerve sheath tumors. , 2018, Pathology, research and practice.

[11]  W. Wadsak,et al.  Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18F]FDG‐PET imaging. Is it of value in asymptomatic patients? , 2018, Pediatric blood & cancer.

[12]  Arie Perry,et al.  Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. , 2017, Human pathology.

[13]  D. Evans,et al.  Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1 , 2017, Clinical Cancer Research.

[14]  D. Evans,et al.  Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders , 2017, Clinical Cancer Research.

[15]  M. van de Rijn,et al.  MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation , 2017, Nature Communications.

[16]  C. Swallow,et al.  Needle tract seeding after percutaneous biopsy of sarcoma: Risk/benefit considerations , 2017, Cancer.

[17]  N. Ratner,et al.  Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. , 2016, The New England journal of medicine.

[18]  K. London,et al.  The Role of [18F]FDG-PET/CT in Predicting Malignant Transformation of Plexiform Neurofibromas in Neurofibromatosis-1 , 2016, International journal of surgical oncology.

[19]  S. Peltonen,et al.  Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Schiffman,et al.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. , 2016, The Lancet. Oncology.

[21]  D. Pan,et al.  Neurofibromatosis type 1 associated with pheochromocytoma and gastrointestinal stromal tumors: A case report and literature review. , 2016, Oncology letters.

[22]  S. Steinberg,et al.  SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN). , 2016 .

[23]  S. Hirota,et al.  Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I , 2015, Journal of Gastroenterology.

[24]  R. Wahl,et al.  18F-FDG PET/CT Qualitative and Quantitative Evaluation in Neurofibromatosis Type 1 Patients for Detection of Malignant Transformation: Comparison of Early to Delayed Imaging With and Without Liver Activity Normalization , 2015, The Journal of Nuclear Medicine.

[25]  K. Camphausen,et al.  Radiation Therapy in Management of Sporadic and Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors , 2014, Front. Oncol..

[26]  D. Gutmann,et al.  Neurofibromatosis type 1: a multidisciplinary approach to care , 2014, The Lancet Neurology.

[27]  L. Lorenzon,et al.  Gastrointestinal Stromal Tumors Associated with Neurofibromatosis 1: A Single Centre Experience and Systematic Review of the Literature Including 252 Cases , 2013, International journal of surgical oncology.

[28]  D. Aust,et al.  Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I. , 2013, The American journal of medicine.

[29]  K. S. Hall,et al.  Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1 , 2012, Neuro-oncology.

[30]  G. Treglia,et al.  Usefulness of Whole-Body Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Patients with Neurofibromatosis Type 1: A Systematic Review , 2012, Radiology research and practice.

[31]  M. Askenazi,et al.  Quantitative Assessment of Whole-Body Tumor Burden in Adult Patients with Neurofibromatosis , 2012, PloS one.

[32]  A. Folpe,et al.  Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems , 2012, Acta Neuropathologica.

[33]  J. Lasota,et al.  Succinate Dehydrogenase Subunit B (SDHB) Is Expressed in Neurofibromatosis 1-Associated Gastrointestinal Stromal Tumors (Gists): Implications for the SDHB Expression Based Classification of Gists , 2011, Journal of Cancer.

[34]  C. Yeo,et al.  Periampullary and Duodenal Neoplasms in Neurofibromatosis Type 1: Two Cases and an Updated 20-Year Review of the Literature Yielding 76 Cases , 2010, Journal of Gastrointestinal Surgery.

[35]  R. Grimer,et al.  Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours , 2009, Sarcoma.

[36]  M. Harada,et al.  A case of von Recklinghausen's disease with coincident malignant peripheral nerve sheath tumor and gastrointestinal stromal tumor. , 2009, The journal of medical investigation : JMI.

[37]  H. Moch,et al.  Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. , 2008, Endocrine-related cancer.

[38]  J. Drake,et al.  Massive plexiform neurofibromas in childhood: natural history and management issues. , 2007, Journal of neurosurgery.

[39]  A. Ferrari,et al.  Soft‐tissue sarcomas in children and adolescents with neurofibromatosis type 1 , 2007, Cancer.

[40]  S. Steinberg,et al.  NF1 plexiform neurofibroma growth rate by volumetric MRI , 2007, Neurology.

[41]  J. Lasota,et al.  Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.

[42]  L. Sobin,et al.  Gastrointestinal Stromal Tumors in Patients With Neurofibromatosis 1: A Clinicopathologic and Molecular Genetic Study of 45 Cases , 2006, The American journal of surgical pathology.

[43]  M. Fukayama,et al.  Gastrointestinal Stromal Tumors of Neurofibromatosis Type I (von Recklinghausen's Disease) , 2005, The American journal of surgical pathology.

[44]  K. Ness,et al.  Long‐term survival probabilities for childhood rhabdomyosarcoma , 2005, Cancer.

[45]  L. Sobin,et al.  From the archives of the AFIP: abdominal neoplasms in patients with neurofibromatosis type 1: radiologic-pathologic correlation. , 2005, Radiographics : a review publication of the Radiological Society of North America, Inc.

[46]  James R. Anderson,et al.  Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. , 2004, The Journal of pediatrics.

[47]  Q. Yang,et al.  Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. , 2001, American journal of human genetics.

[48]  W. Linehan,et al.  von Recklinghausen's disease and pheochromocytomas. , 1999, The Journal of urology.

[49]  J. Woodruff Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. , 1999, American journal of medical genetics.

[50]  B. Korf,et al.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. , 1997, JAMA.

[51]  A. Odén,et al.  Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population , 1997, Cancer.

[52]  J. Zeller,et al.  Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. , 1996, Archives of dermatology.

[53]  M. Zöller,et al.  Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Göteborg, Sweden. , 1995, Acta dermato-venereologica.

[54]  F. Mitros,et al.  CT findings of plexiform neurofibromatosis involving the ileum and its mesentery. , 1994, Clinical imaging.

[55]  T. D. Ghrist GASTROINTESTINAL INVOLVEMENT IN NEUROFIBROMATOSIS. , 1963, Archives of internal medicine.

[56]  A. Raghunathan,et al.  H3K27 trimethylation loss in malignant peripheral nerve sheath tumor: a systematic review and meta-analysis with diagnostic implications , 2019, Journal of Neuro-Oncology.

[57]  K. Hunt,et al.  Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. , 2017, Journal of neurosurgery.

[58]  L. Qin,et al.  Oncologic Outcomes of Sporadic, Neurofibromatosis-Associated, and Radiation-Induced Malignant Peripheral Nerve Sheath Tumors , 2012, Annals of Surgical Oncology.

[59]  Y. Hataya,et al.  A case of neurofibromatosis type 1 coinciding with bilateral pheochromocytomas, multiple gastrointestinal stromal tumors, and malignant peripheral nerve sheath tumor. , 2012, Internal medicine.

[60]  A. Agaimy,et al.  Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen's disease): clinicopathological spectrum with pathogenetic considerations. , 2012, International journal of clinical and experimental pathology.

[61]  S. Giustini,et al.  Gastrointestinal and Retroperitoneal Manifestations of Type 1 Neurofibromatosis , 2009, Journal of Gastrointestinal Surgery.